EFEKTIVITAS ANTIBAKTERI EKSTRAK DAUN TEH HIJAU TERHADAP BAKTERI MYCOBACTERIUM TUBERCULOSIS
Main Article Content
Abstract
Tuberculosis is still a global health problem. Prolonged treatment of tuberculosis and using several anti-tuberculosis drugs (OAT) can cause side effects, one of which is multidrug resistance. Cases of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium strains continue to increase. . Research and development of active compounds from medicinal plants to achieve more effective tuberculosis treatment is still being promoted. This research aims to determine the potential and effectiveness of green tea plant (Camellia sinensis) leaf extract in inhibiting the growth of Mycobacterium tuberculosis strain H37Rv bacteria using the LJ (Lowenstein-Jensen) method in vitro. The research samples used were green tea plant leaves (Camellia sinensis) obtained from the Malino Village Tea Plantation, Tinggi Moncong Regency, Gowa District, South Sulawesi. The leaf extract was made in 4 types of concentrations, namely 10, 20, 50 and 100 µg/ml, each of which was tested against the clinical isolate of Mycobacterium tuberculosis strain H37Rv using the LJ (Lowenstein-Jensen) method as the standard for tuberculosis examination. Of the four extracts tested in vitro, only extract concentrations of 50 and 100 µg/ml were able to very strongly inhibit and kill the growth of Mycobacterium tuberculosis strain H37Rv (inhibition percentage of 100%), not a single bacterial colony growth was found during the observation period. The percentage of inhibition of green tea plant leaves (Camellia sinensis) is the same as the percentage of inhibition of the drug rifampicin. Thus, the leaves of the green tea plant (Camellia sinensis) with concentrations of 50 and 100 µg/ml have potential antituberculosis activity and are prospective to be developed as antituberculosis from natural ingredients, and also as an additional therapeutic complement for TB.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the journal, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- That its publication has been approved by all the author(s) and by the responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
2. Kementerian Kesehatan Republik Indonesia. Situasi TBC di Indonesia. Diperoleh dari: https://www.tbindonesia.or.id/page/view/11/situasi-tbc-di-indonesia [Diakses 2022 Januari 20].
3. World Health Organization. Multidrug-resistant tuberculosis (MDR-TB) 20120 Update. Diperoleh dari: www.who.int/tb/challenges/mdr [Diakses 2022 Januari 20].
4. Anggita Mirzautika, Isnaeni, Djoko Agus Purwanto, 2019. Anti-Mycobacterium tuberculosis Activity of (-)-Epigallocatechin-gallate (EGCG) and First-line Antituberculosis Drugs Combination. Jurnal Kefarmasian Indonesia Vol.10 No.1- Februari 2020:59-66.
5. Green tea plant compound may help fight TB: Study, 2019. ETHealthWord.Com.
6. Anand PK, Kaul D, Sharma M. Green tea polyphenol inhibits Mycobacterium tuberculosis survival within human macrophages. The International Journal of Biochemistry & Cell Biology. 2006 Nov;38:600-609.
7. Koech KR, Wachira FN, Ngure RM, Wanyoko JK, Bii CC, Karori SM, et al.Antimicrobial, synergistic and antioxidant activities of tea polyphenols. In: A. Méndez-Vilas, Ed.Microbial pathogens and strategies for combating them: science, technology and education. Badajoz: Formatex Research Center; 2013. p. 971-981.
8. Gaby Maulida Nurdin dan Irnayanti Bahar, 2018. Skrining Antituberkulosis Ekstrak Tanaman Obat Lokal terhadap Mycobacterium tuberculosis Galur h37rv dan he dengan Metode Lowenstein-Jensen.
9. Sivakumar, A., Jayaraman, G. 2011. Antituberculosis activity of commonly used medicinal plants of south India. Journal of Medicinal Plants Research 5(31), pp. 6881- 6884.
10. Das S, Tanwar J, Hameed S, Fatima Z, 2014. Antimicrobial potential of epigallocatechin-3-gallate(EGCG): a green tea polyphenol. Journal of Biochemical and Pharmacological Research. 2(3):167-174.
11. Fatima Z, Hameed S, Islam N, 2012. Epigallocatechin-3-gallate(EGCG), a green tea polyphenol suppresses bacilli-inducedaugmented expression of Mycobacterium tuberculosis 85Band proinflammatory TNF-α in human monocytes. International Journal of Scientific and Research Publications. 2(2):1-6.
12. Fatima Z, Hameed S, Islam N, 2013. Green tea polyphenol (EGCG) is a better inhibitor of TNF-α and MTB 85B antigen in human monocytes than known antioxidants and antibiotics. The Journal of Infectious Diseases.